Grew total revenue to $150.3 million and testing revenue to $145.7 million , representing increases of 15% and 19% year-over-year, respectively Conference call and webcast today at...
Barchart Research What to Expect from VCYT Earnings VCYT Generated July 29, 2026 Current Price $55.71 EPS Estimate $$0.29 Consensus Rating Moderate Buy Average Move 14.82% Veracyte's Earnings Decline Arrives...
SOUTH SAN FRANCISCO, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will be participating in the following investor...
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the second quarter 2026 after the close of market on Thursday, July...
Genomic test using whole-transcriptome next-generation sequencing technology will be available to order on June 8 The Prosigna test predicts chemotherapy benefit and quantifies...
Study provides first Level 1B evidence for genomic-guided decisions on triplet therapy in advanced disease Additional ASCO data reinforce Decipher Prostate’s utility...
Highest level of prospective evidence supports test-directed chemotherapy decisions in broadest high-risk population to-date, including premenopausal women and patients with extensive lymph node involvement...
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that it will host a conference call and webcast on Monday, June 1, 2026 at 8:30 a.m. ET to discuss data from...
Additional Data from ENZAMET Study Show How Decipher Can Help Metastatic Prostate Cancer Patients Avoid Unnecessary Treatment and Enable More Personalized Care